BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

442 related articles for article (PubMed ID: 34237031)

  • 21. Kinase gene fusions: roles and therapeutic value in progressive and refractory papillary thyroid cancer.
    Liu M; Chen P; Hu HY; Ou-Yang DJ; Khushbu RA; Tan HL; Huang P; Chang S
    J Cancer Res Clin Oncol; 2021 Feb; 147(2):323-337. PubMed ID: 33387037
    [TBL] [Abstract][Full Text] [Related]  

  • 22. An impressive response with larotrectinib in a patient with a papillary thyroid carcinoma harboring an SQSTM1-NTRK1 fusion.
    Bargas S; Mc Leer A; Mondet J; Chabre O; Laramas M
    Eur J Endocrinol; 2022 Feb; 186(4):K5-K8. PubMed ID: 35118995
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The RET oncogene in papillary thyroid carcinoma.
    Prescott JD; Zeiger MA
    Cancer; 2015 Jul; 121(13):2137-46. PubMed ID: 25731779
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Novel rearrangements involving the RET gene in papillary thyroid carcinoma.
    Staubitz JI; Schad A; Springer E; Rajalingam K; Lang H; Roth W; Hartmann N; Musholt TJ
    Cancer Genet; 2019 Jan; 230():13-20. PubMed ID: 30466862
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Genetic Alterations in Pediatric Thyroid Cancer Using a Comprehensive Childhood Cancer Gene Panel.
    Alzahrani AS; Alswailem M; Alswailem AA; Al-Hindi H; Goljan E; Alsudairy N; Abouelhoda M
    J Clin Endocrinol Metab; 2020 Oct; 105(10):. PubMed ID: 32556222
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Successful combination of selpercatinib and radioiodine after pretherapeutic dose estimation in RET-altered thyroid carcinoma.
    Werner RA; Sayehli C; Hänscheid H; Higuchi T; Serfling SE; Fassnacht M; Goebeler ME; Buck AK; Kroiss M
    Eur J Nucl Med Mol Imaging; 2023 May; 50(6):1833-1834. PubMed ID: 36522435
    [No Abstract]   [Full Text] [Related]  

  • 27. Pitfalls in RET Fusion Detection Using Break-Apart FISH Probes in Papillary Thyroid Carcinoma.
    Liu Y; Wu S; Zhou L; Guo Y; Zeng X
    J Clin Endocrinol Metab; 2021 Mar; 106(4):1129-1138. PubMed ID: 33382428
    [TBL] [Abstract][Full Text] [Related]  

  • 28. NTRK fusion analysis reveals enrichment in Middle Eastern BRAF wild-type PTC.
    Kong Y; Bu R; Parvathareddy SK; Siraj AK; Siraj N; Al-Sobhi SS; Al-Dayel F; Al-Kuraya KS
    Eur J Endocrinol; 2021 Apr; 184(4):503-511. PubMed ID: 33524004
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Response to RET-Specific Therapy in
    Dias-Santagata D; Lennerz JK; Sadow PM; Frazier RP; Govinda Raju S; Henry D; Chung T; Kherani J; Rothenberg SM; Wirth LJ
    Thyroid; 2020 Sep; 30(9):1384-1389. PubMed ID: 32292131
    [No Abstract]   [Full Text] [Related]  

  • 30. BRAFV600E mutation, but not RET/PTC rearrangements, is correlated with a lower expression of both thyroperoxidase and sodium iodide symporter genes in papillary thyroid cancer.
    Romei C; Ciampi R; Faviana P; Agate L; Molinaro E; Bottici V; Basolo F; Miccoli P; Pacini F; Pinchera A; Elisei R
    Endocr Relat Cancer; 2008 Jun; 15(2):511-20. PubMed ID: 18509003
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Overcoming MET-Dependent Resistance to Selective RET Inhibition in Patients with RET Fusion-Positive Lung Cancer by Combining Selpercatinib with Crizotinib.
    Rosen EY; Johnson ML; Clifford SE; Somwar R; Kherani JF; Son J; Bertram AA; Davare MA; Gladstone E; Ivanova EV; Henry DN; Kelley EM; Lin M; Milan MSD; Nair BC; Olek EA; Scanlon JE; Vojnic M; Ebata K; Hechtman JF; Li BT; Sholl LM; Taylor BS; Ladanyi M; Jänne PA; Rothenberg SM; Drilon A; Oxnard GR
    Clin Cancer Res; 2021 Jan; 27(1):34-42. PubMed ID: 33082208
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Novel TG-FGFR1 and TRIM33-NTRK1 transcript fusions in papillary thyroid carcinoma.
    Pfeifer A; Rusinek D; Żebracka-Gala J; Czarniecka A; Chmielik E; Zembala-Nożyńska E; Wojtaś B; Gielniewski B; Szpak-Ulczok S; Oczko-Wojciechowska M; Krajewska J; Polańska J; Jarząb B
    Genes Chromosomes Cancer; 2019 Aug; 58(8):558-566. PubMed ID: 30664823
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Genetic landscape of papillary thyroid carcinoma in the Chinese population.
    Liang J; Cai W; Feng D; Teng H; Mao F; Jiang Y; Hu S; Li X; Zhang Y; Liu B; Sun ZS
    J Pathol; 2018 Feb; 244(2):215-226. PubMed ID: 29144541
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pediatric, Adolescent, and Young Adult Thyroid Carcinoma Harbors Frequent and Diverse Targetable Genomic Alterations, Including Kinase Fusions.
    Vanden Borre P; Schrock AB; Anderson PM; Morris JC; Heilmann AM; Holmes O; Wang K; Johnson A; Waguespack SG; Ou SI; Khan S; Fung KM; Stephens PJ; Erlich RL; Miller VA; Ross JS; Ali SM
    Oncologist; 2017 Mar; 22(3):255-263. PubMed ID: 28209747
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Oncogenic alterations in papillary thyroid cancers of young patients.
    Sassolas G; Hafdi-Nejjari Z; Ferraro A; Decaussin-Petrucci M; Rousset B; Borson-Chazot F; Borbone E; Berger N; Fusco A
    Thyroid; 2012 Jan; 22(1):17-26. PubMed ID: 22150560
    [TBL] [Abstract][Full Text] [Related]  

  • 36. RET/PTC Gene Rearrangements in Thyroid Carcinogenesis: Assessment and Clinico-Pathological Correlations.
    Khan MS; Qadri Q; Makhdoomi MJ; Wani MA; Malik AA; Niyaz M; Masoodi SR; Andrabi KI; Ahmad R; Mudassar S
    Pathol Oncol Res; 2020 Jan; 26(1):507-513. PubMed ID: 30467698
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pattern of radiation-induced RET and NTRK1 rearrangements in 191 post-chernobyl papillary thyroid carcinomas: biological, phenotypic, and clinical implications.
    Rabes HM; Demidchik EP; Sidorow JD; Lengfelder E; Beimfohr C; Hoelzel D; Klugbauer S
    Clin Cancer Res; 2000 Mar; 6(3):1093-103. PubMed ID: 10741739
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The molecular and gene/miRNA expression profiles of radioiodine resistant papillary thyroid cancer.
    Colombo C; Minna E; Gargiuli C; Muzza M; Dugo M; De Cecco L; Pogliaghi G; Tosi D; Bulfamante G; Greco A; Fugazzola L; Borrello MG
    J Exp Clin Cancer Res; 2020 Nov; 39(1):245. PubMed ID: 33198784
    [TBL] [Abstract][Full Text] [Related]  

  • 39. FDA Approval Summary: Selpercatinib for the Treatment of Lung and Thyroid Cancers with
    Bradford D; Larkins E; Mushti SL; Rodriguez L; Skinner AM; Helms WS; Price LSL; Zirkelbach JF; Li Y; Liu J; Charlab R; Turcu FR; Liang D; Ghosh S; Roscoe D; Philip R; Zack-Taylor A; Tang S; Kluetz PG; Beaver JA; Pazdur R; Theoret MR; Singh H
    Clin Cancer Res; 2021 Apr; 27(8):2130-2135. PubMed ID: 33239432
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Identification of a Recurrent LMO7-BRAF Fusion in Papillary Thyroid Carcinoma.
    He H; Li W; Yan P; Bundschuh R; Killian JA; Labanowska J; Brock P; Shen R; Heerema NA; de la Chapelle A
    Thyroid; 2018 Jun; 28(6):748-754. PubMed ID: 29768105
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.